Tuesday, 17 March 2026
  
Login

Australia's most trusted
source of pharma news

Tuesday, 17 March 2026
News

Arrotex inks cardio drug deal

Posted 17 March 2026 AM

Arrotex Pharmaceuticals and George Medicines have joined forces to bring GMRx2, a triplet combo therapy for hypertension to Australia and New Zealand, as early as next year.

The collaboration brings together two Australian organisations with a shared commitment to improving outcomes for patients with cardiometabolic disease – an area of significant unmet clinical need. Low adherence to complicated treatment regimens involving multiple concurrent therapies can significantly undermine patients’ ability to achieve adequate blood pressure control.

To see the whole article, please login

Popular

Minister wins blockbuster price cut case
Last ditch effort to keep exclusivity
CEO pay packet rockets by 75%
GSK tops Kosi fundraising peak
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home